Cases & Deals

  • Home
  • Practices
  • Amolyt Pharma raises $80 million in Series B financing round

Share

Amolyt Pharma raises $80 million in Series B financing round

September 2021

Client(s) Amolyt Pharma

Jones Day advised Amolyt Pharma, a French based company engaged in the research and development of new therapeutic strategies for the treatment of rare endocrine and metabolic diseases, in connection with its $80 million Series B round of financing co-led by Sectoral Asset Management and Andera Partners.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.